- Home
- AKA vs MCRB Comparison
AKA vs MCRB Comparison
Compare AKA & MCRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKA
- MCRB
- Stock Information
- Founded
- AKA 2018
- MCRB 2010
- Country
- AKA United States
- MCRB United States
- Employees
- AKA N/A
- MCRB N/A
- Industry
- AKA Catalog/Specialty Distribution
- MCRB Biotechnology: Pharmaceutical Preparations
- Sector
- AKA Consumer Discretionary
- MCRB Health Care
- Exchange
- AKA Nasdaq
- MCRB Nasdaq
- Market Cap
- AKA 110.4M
- MCRB 125.7M
- IPO Year
- AKA 2021
- MCRB 2015
- Fundamental
- Price
- AKA $10.59
- MCRB $16.69
- Analyst Decision
- AKA Strong Buy
- MCRB Hold
- Analyst Count
- AKA 3
- MCRB 4
- Target Price
- AKA $24.33
- MCRB $73.67
- AVG Volume (30 Days)
- AKA 3.3K
- MCRB 131.1K
- Earning Date
- AKA 08-06-2025
- MCRB 08-06-2025
- Dividend Yield
- AKA N/A
- MCRB N/A
- EPS Growth
- AKA N/A
- MCRB N/A
- EPS
- AKA N/A
- MCRB 10.22
- Revenue
- AKA $598,107,000.00
- MCRB N/A
- Revenue This Year
- AKA $6.60
- MCRB N/A
- Revenue Next Year
- AKA $4.14
- MCRB N/A
- P/E Ratio
- AKA N/A
- MCRB $1.64
- Revenue Growth
- AKA 7.67
- MCRB N/A
- 52 Week Low
- AKA $7.00
- MCRB $6.53
- 52 Week High
- AKA $32.25
- MCRB $26.40
- Technical
- Relative Strength Index (RSI)
- AKA 41.02
- MCRB 64.72
- Support Level
- AKA $11.11
- MCRB $14.06
- Resistance Level
- AKA $11.38
- MCRB $17.52
- Average True Range (ATR)
- AKA 0.41
- MCRB 1.38
- MACD
- AKA -0.07
- MCRB 0.13
- Stochastic Oscillator
- AKA 4.25
- MCRB 84.54
About AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is an online fashion retailer focused on acquiring and accelerating the growth of next-generation, digitally native fashion brands targeting Gen Z and Millennial customers. The brands of the company are two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company derives maximum revenue from Australia/New Zealand.
About MCRB Seres Therapeutics Inc.
Seres Therapeutics Inc is a microbiome therapeutics platform company operating in the United States. The company is engaged in developing biological drugs which are referred as ecobiotic microbiome therapeutics. The drugs discovered by the company are designed to restore health by repairing the function of a dysbiotic microbiome. The company focuses on implementing its microbiome therapeutics platform to develop ecobiotic microbiome therapeutics that treat dysbiosis in the colonic microbiome. SER-109, the company's product, is designed to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon. In addition, the company is involved in developing SER-262, SER-287, and SER-401.